Company Monitoring Page for JNJ

latest headlines for company on cafepharma

CVS formulary knocks Lilly, BI's Jardiance in favor of J&J's Invokana
Fierce Pharma
Wed, 08/2/17 - 11:57 am
Tags:
formulary, Eli Lilly, Boehringer Ingelheim, JNJ, Invokana, diabetes, CVS Caremark
Johnson & Johnson shows off under-pressure Stelara's latest indication—Crohn's—in new DTC spot
Fierce Pharma
Wed, 08/2/17 - 11:30 am
Tags:
JNJ, Stelara, Crohn's Disease, drug advertising, DTC ads
J&J arthritis drug sirukumab raises safety concerns -FDA staff
Yahoo/Reuters
Mon, 07/31/17 - 09:43 am
Tags:
JNJ, FDA, sirukumab, rheumatoid arthritis
J&J inks $879M vaccine deal with Bavarian Nordic
BioPharma Dive
Fri, 07/28/17 - 11:29 am
Tags:
JNJ, vaccines, Bavarian Nordic, Janssen, hepatitis B
Which Medtech CEOs Made the Most Last Year?
Qmed
Fri, 07/28/17 - 11:09 am
Tags:
devices, CEOs, executive pay, JNJ, Alex Gorsky, GE, Jeffrey Immelt, Abbott Labs, Miles White, 3M, Inge Thulin
Merck undercuts Pfizer on Remicade biosimilar price
BioPharma Dive
Wed, 07/26/17 - 10:18 pm
Tags:
Merck, Pfizer, Remicade, drug pricing, biosimilars, Renflexis, JNJ
J&J reports positive results for HIV regimen
BioPharma Dive
Wed, 07/26/17 - 11:21 am
Tags:
JNJ, HIV, Gilead Sciences, Darunavir
Lilly, J&J, AbbVie and WuXi help seed a regenerative medicine upstart
Endpoints
Wed, 07/26/17 - 09:49 am
Tags:
Eli Lilly, JNJ, AbbVie, WuXi, regenerative medicine, Rodeo Therapeutics
Johnson & Johnson rolls Pulsar Vascular, Neuravi into new Cerenovus neurovascular biz
Mass Device
Tue, 07/25/17 - 08:25 am
Tags:
JNJ, M&A, Pulsar Vascular, Neuravi, Cerenovus, devices
J&J touts first-in-human data for HIV vaccine
Drug Delivery Business News
Tue, 07/25/17 - 12:00 am
Tags:
JNJ, HIV, vaccines, Janssen
Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta
Endpoints
Mon, 07/24/17 - 10:40 am
Tags:
Samsung Bioepis, Remicade, FDA, biosimilars, JNJ, GSK, Benlysta, lupus
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
Motley Fool
Sun, 07/23/17 - 11:47 am
Tags:
Biogen, aducanumab, JNJ, apalutamide, Eli Lilly, abemaciclib, AbbVie, Rova-T, Celgene, ozanimod
How did Johnson & Johnson beat back Remicade's biosim? Call it the art of the deal
Fierce Pharma
Thu, 07/20/17 - 11:18 am
Tags:
JNJ, Remicade, biosimilars, Pfizer, Inflectra
Johnson & Johnson CEO Gorsky: Verb Surgical robotics program ‘on track’
Mass Device
Wed, 07/19/17 - 07:50 pm
Tags:
JNJ, Pharma CEOs, Alex Gorsky, Verb Surgical, surgical robots, devices
J&J's Invokana continues downward market-share spiral as Lilly, BI's Jardiance advances
Fierce Pharma
Wed, 07/19/17 - 07:47 pm
Tags:
JNJ, Invokana, Eli Lilly, Boehringer Ingelheim, Jardiance, diabetes
Despite Falling Drug Sales, Johnson & Johnson Remains Optimistic
Motley Fool
Tue, 07/18/17 - 10:54 pm
Tags:
JNJ, earnings
5 Big Pharma Stocks With the Best Drug Pipelines
Motley Fool
Tue, 07/18/17 - 11:32 am
Tags:
Big Pharma, Roche, AstraZeneca, AbbVie, Gilead Sciences, JNJ
4 Things That Matter When Johnson & Johnson Reports Its Second-Quarter Results
Motley Fool
Tue, 07/18/17 - 09:20 am
Tags:
JNJ, earnings
Johnson & Johnson’s 2Q17 Estimates: Medical Devices
Market Realist
Mon, 07/17/17 - 10:03 am
Tags:
JNJ, earnings, devices, Ethicon, Animas, LifeScan, Biosense Webster, DePuy Synthes, Mentor
J&J's Tremfya approved, further crowding IL-inhibitor market
BioPharma Dive
Sat, 07/15/17 - 11:31 am
Tags:
JNJ, Tremfya, psoriasis, Interleukin-inhibitors, guselkumab

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.